The Philadelphia Chromosome Detection in Chronic Myeloid Leukemia in Karbala City
DOI:
https://doi.org/10.51699/ijhsms.v2i11.2804Keywords:
Chronic myeloid leukemia, BCR-ABL, Philadelphia chromosomeAbstract
Background: The mutual transposition t (9;22) (q34; q11) results in the Philadelphia chromosome (Ph), which is an ideal marker of chronic myeloid leukemia (CML). The proto-oncogene tyrosine-protein kinase (BCR-ABL1) oncogenic breakpoint cluster region-protein with enhanced tyrosine kinase action is encoded by this fusion gene. The kinase movement is measurable for cell proliferation, diversity inhibition, and cell death confrontation. Styles of representation in isolate BCR-ABL1 transcripts change when CML progresses transitioning from a chronic to an expedited phase and ultimately to the blast phase. Every BCR-ABL1 transcription is concomittant with a specific leukemia phenotype that expects treatment clinical outcome and reaction prognosis. The Ph is seen in acute lymphoblastic leukemia, acute myeloid leukemia, and motley-type acute leukemia, in addition to CML.
Aim of the study: to give a view of the clinical diagnostic importance of Philadelphia chromosome CML and role of Philadelphia in comparison to morphology.
Methods: A total of 180 patients had developed leukocytosis with severe Lf-shift by blood film. Data for patients, as age and sex, were collected. Blood samples, including CBC with total WBC, and differential counts, were performed using 5-parts differential URIT autoanalyzer hematology.
Results: A total of 180 patients with leukocytosis, 150 of them had Philadelphia chromosome-positive with a mean age of 52.86 ± 13.9 (range: 29-80) years were collected. Sixty (50%) cases were male and sixty % were female and 30 cases of them were Philadelphia negative with a mean age of 56.1 ± 14.8 years, 17 cases were male and 13 cases were female. There was an important difference between the two groups. In this study, the mean ±SD for Philadelphia positive patients was found to be a very highly significant difference when compared with Philadelphia negative group, at the level of significance (<0.001) by student T-Test.
Conclusion: The research of myeloproliferative disorders has many goals: diagnostic, therapeutic, predictive and follow-up, all of which contribute to better outpatient therapy.
Downloads
References
Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–1459.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015; 94 Suppl 2:S241–S247.
Nikhitha P.M, Sunil. M, Deepu. Prasad. A Study to Assess the Knowledge and Illness Perception of Parents of Children with Leukemia, Attending Oncology units, at AIMS, Kochi. Int. J. Nur. Edu. and Research 3(4): Oct.-Dec., 2015; Page 344-350.
Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 2015; 34(3):53.
Protein tyrosine kinase Abl promotes hepatitis C virus particle assembly via interaction with viral substrate activator NS5A.Miyamoto D, et al. J Biol Chem, 2022 Apr. PMID 35257746, Free PMC Article
ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Luttman JH, et al. Cell Rep, 2021 Oct 26. PMID 34706244, Free PMC Article.
Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009; 113:4489–4496.
Sangeeta Mahaur, Sukirti Upadhyay, Ravi Raj Pal. Indolizine: In-Silico Identification of Inhibitors against Mutated BCR-ABL Protein of Chronic Myeloid Leukemia. Res. J. Pharmacology and Pharmacodynamics.2020; 12(4):151-158.
Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100(6): 1965–1971.
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99(10): 3530–3539.
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph + CML or relapsed/refractory Ph + ALL. Int J Hematol. 2009; 89(5): 679–688.
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011; 121(1): 396–409.
Rafiei A, Mian AA, Doring C, Metodieva A, Oancea C, Thalheimer FB, et al. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. PLoS Genet. 2015; 11(4): e1005144.
Zhang LJ, Gan YM, Yu L. Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia. Med Oncol. 2015; 32(1): 382.
Verrma SP, Dutta TK, Vinod KV, Dubashi B, Ariga KK. Philadelphia chromosome positive pre-T cell acute lymphoblastic leukemia: a rare case report and short review. Indian J Hematol Blood Transfus. 2014; 30(Suppl 1): 177–179.
Choi W, Kim M, Lim J, Han K, Lee S, Lee JW, et al. Four cases of chronic myelogenous leukemia in mixed phenotype blast phase at initial presentation mimicking mixed phenotype acute leukemia with t(9;22) Ann Lab Med. 2014; 34(1): 60–63.
Matutes E, Pickl WF, Van’t Veer M, Morilla R, Swansbury J, Strobl H, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011; 117(11): 3163–3171.
Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102(3): 83–87.
Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011; 117:3163.
Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø. Acute myeloid leukemia with the t (8;21) translocation: Clinical consequences and biological implications. J Biomed Biotechnol 2011;2011:104631
M. Sravani, N. Duganath, Deepak Reddy Gade, Sandeep Reddy C.H.. Insilico Analysis and Docking of Imatinib Derivatives Targeting BCR-ABL Oncoprotein for Chronic Myeloid Leukemia. Asian J. Research Chem. 5(1): January 2012; Page 153-158.
Mohamed Zerein Fathima, T.S. Shanmugarajan, S. Satheesh Kumar, B.V.Venkata Nagarjuna Yadav. Comparative in Silico Docking Studies of Hinokitiol with Sorafenib and Nilotinib against Proto-Oncogene Tyrosine-Protein Kinase(ABL1) and Mitogen-activated Protein Kinase (MAPK) to Target Hepatocellular Carcinoma. Research J. Pharm. and Tech. 2017; 10(1): 257-262.
Balakrishnan Purushothaman, Nagarasan Suganthi , Arunachalam Jothi, Kumaran Shanmugam. Molecular Docking Studies of potential anticancer agents from Ocimum basilicum L. against human colorectal cancer regulating genes: An insilico approach. Research J. Pharm. and Tech. 2019; 12(7): 3423-3427.
Jean-Claude Chomel and Ali G., Turhan Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy , Oncotarget. 2011 Sep; 2(9): 713–727
Kiranmai Gudimetla, Orsu Prabhakar, Abhisek Pal. Review on Pathophysiological and Pharmacotherapeutic approach on Chronic Myeloid Leukemia. Research J. Pharm. and Tech 2020; 13(6): 2971-2976.
Ankit Darji, Praful Bharadia. Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients. Research Journal of Pharmacy and Technology. 2021; 14(8):4092-0.
Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. Asian J. Res. Pharm. Sci. 2020; 10(2):100-102.
P. Ravi Sankar, K. Saisneha Latha, A. Bhavani Sailu, SK. Taheera, B. Madhuri. Development and Validation of RP-HPLC Method for the Determination of Pazopanib Hydrochloride (A Tyrosine Kinase Inhibitor) in Pharmaceutical Dosage Form. Research J. Pharm. and Tech 2021; 14(3):1549-1554.
Muhammed A. H. Aldabagh, Sahar S. Karieb, Ali N. Yassen, Saddam H. Jaber, Mohammed S. Abbas, Ali M. Jawad. Reading of Immune picture in Chronic Myeloid Leukemia in Iraqi Patients. Research J. Pharm. and Tech. 2019; 12(4):1910-1914.
